Research programme: neurodegenerative diseases therapeutics - Cognition Therapeutics

Drug Profile

Research programme: neurodegenerative diseases therapeutics - Cognition Therapeutics

Alternative Names: amyloid beta-protein inhibitors - Cognition Therapeutics; CT 0093; CT 0109; CT 013441; CT 013461

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cognition Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Progesterone receptor antagonists; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 29 Sep 2016 Preclinical trials in Parkinson's disease in USA (unspecified route)
  • 21 May 2014 Cognition Therapeutics receives funding from the National Institute on Aging for development of small molecule soluble amyloid beta receptor antagonists in Alzheimer's disease
  • 04 Apr 2014 Preclinical development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top